SEC Filing Summary: Ra Medical Systems, Inc. (RMED)
Business Context and Reporting Period
This Form 8-K was filed by Ra Medical Systems, Inc. on August 19, 2020, reporting an event that occurred on August 16, 2020. The registrant is a Delaware corporation with principal executive offices in Carlsbad, California, and its common stock trades on the New York Stock Exchange under the symbol RMED. The company is classified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance and does not contain financial statements or performance metrics.
Material Changes
The material change reported is a governance adjustment regarding the Board of Directors. Specifically, the Board resolved to reallocate a Class I director to Class II. Consequently, Joan Stafslien, previously serving as a Class I director, was appointed as a Class II director effective August 16, 2020.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the director class reallocation.
Key Facts for Investor Verification
- Joan Stafslien's director class was changed from Class I to Class II on August 16, 2020.
- The filing contains no financial data or operational updates.
- The company remains an emerging growth company as of the filing date.